ARCA biopharma, Inc. (NASDAQ:ABIO) Files An 8-K Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

ARCA biopharma, Inc. Exhibit
EX-99.1 2 abio-ex991_6.htm EX-99.1 abio-ex991_6.htm   Exhibit 99.1         ARCA Biopharma announces GENETIC-AF Data and Safety Monitoring Board recommendation to complete phase 2b GENETIC-AF clinical trial based on efficacy and safety data in Phase 2b interim analysis ————————————————————————————————– ARCA Estimates Reporting Top-line Phase 2B Data in the First Quarter of 2018 ————————————————————————————————– Gencaro Development Program Has Been Granted Fast Track Designation by U.S. FDA Westminster,…
To view the full exhibit click here

About ARCA biopharma, Inc. (NASDAQ:ABIO)

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.